The aim of the Translational Therapeutics Group is to better understand the biology of prostate, and other advanced cancers, to identify therapeutic strategies that can be rapidly translated to ‘proof of concept’ clinical studies to improve treatments for advanced cancer.

Prostate cancer is a common cancer, and despite the development of new treatments that have improved the outcome for patients with advanced disease, it continues to be a common cause of cancer death.

Prostate cancer represents a heterogenous disease with multiple molecular subtypes; a better understanding of the underpinning biology will help support the development of new treatments and novel therapeutic strategies to improve the outcome for patients.

Our current research is primarily focused on advanced lethal prostate cancer. The group works to understand the underpinning biology of common molecular subtypes of prostate cancer and interrogate the clinical importance of these, with the aim of developing novel biomarker-treatment combinations to translate to ‘proof of concept’ clinical studies.

Our current research portfolio is focused on understanding protein homeostasis, RNA splicing, apoptosis, and nuclear hormone receptor signalling in advanced cancers. The group works closely with the Cancer Biomarkers Team, Prostate Targeted Cancer Therapies Group, and Drug Development Unit; and collaborates with other groups across The Institute of Cancer Research, nationally and internationally.

Overall, the Translational Therapeutics Group is focused on better understanding pre-clinical prostate cancer biology to support the development of novel therapeutic strategies that can be rapidly translated to clinical studies to improve treatments for advanced cancer.